Strategies for lowering lipoprotein(a): a spotlight on novel pharmacological treatments

Lipoprotein(a) and the Risk for Recurrent Atherosclerotic Cardiovascular Events Among Adults With CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study

“… 3 Novel agents including antisense oligonucleotides and small interfering RNA targeting apolipoprotein(a) have been shown to reduce Lp(a) levels, and there are currently ongoing clinical trials to show their efficacy to prevent recurrent events in adults with ASCVD without severe kidney disease (NCT04023552 and NCT05581303). 4 , 5 It is currently unclear whether high Lp(a) levels confer an increased risk for recurrent ASCVD events specifically in adults with CKD. If high Lp(a) levels are associated with an increased risk for recurrent ASCVD events in adults with CKD, this may represent an opportunity for ASCVD risk reduction in this high-risk population through novel Lp(a)-lowering therapies.…”